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Serum fetuin-A in nondialyzed patients with diabetic nephropa-
thy: Relationship with coronary artery calcification.
Background. Fetuin-A is the most potent circulating inhibitor
of calcium phosphorus precipitation and, possibly, an important
mediator of insulin resistance.
Methods. In order to determine the role of fetuin-A in the
high coronary artery calcification (CAC) burden seen in non-
dialyzed individuals with diabetic nephropathy (DN), post-hoc
analyses of data collected from a cross-sectional study of 88 pa-
tients with type 2 diabetes mellitus was done [age, 40–65 years;
normoalbuminuria, N = 30 (Latinos); DN, N = 58 (Latinos and
African Americans)].
Results. The serum levels of fetuin-A were significantly higher
among Latinos with DN when compared to either African
Americans with DN or Latino diabetics with normoalbumin-
uria. Upon adjusting the data for race/ethnicity, there was a
strong, direct relationship between serum fetuin-A levels and
the CAC score (r =0.22, P =0.038) in the study cohort; however,
a strong interaction between the nephropathy status and rela-
tionship of serum fetuin-A levels with CAC score was present
(DN: r = 0.36, P = 0.006; diabetic controls, r = 0.0, P = 0.98).
Among individuals with DN, the significance of the association
persisted even after controlling the data for other predictors of
CAC (partial r = 0.33, P = 0.018). Furthermore, there was a sig-
nificant direct relationship between serum fetuin-A and serum
triglycerides (partial r = 0.27, P = 0.01) and albumin (partial
r = 0.30, P = 0.005), and an inverse relationship with glomerular
filtration rate (r = −0.24, P = 0.03).
Conclusion. This first study in early stages of diabetic chronic
kidney disease shows that the role of serum fetuin-A may be
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far more complex than previously described. During predialysis
stage of DN, there is a direct relationship between serum fetuin-
A levels and CAC score. The reasons for this association in the
presence of nephropathy are unclear, but may be secondary to
proatherogenic insulin resistance.
In the general population, vascular calcification is in-
variably localized to intimal atherosclerotic plaques, and
the coronary artery calcification (CAC) score, as ascer-
tained by electron-beam computed tomography (EBCT),
reliably predicts plaque burden [1–4]. The intimal cal-
cification associated with atherosclerosis is an active,
cell-mediated process, and is promoted by a variety of
stimuli, such as oxidized low-density lipoprotein [5, 6].
Not only is CAC present in most individuals with chronic
kidney disease (CKD), it is often substantially more
severe than seen among the general population or nor-
moalbuminuric diabetics, respectively [7–11]. Among
individuals with diabetes mellitus or those with CKD,
vascular calcification occurs both in the intima (in associ-
ation with atherosclerosis) and the media; the relative
contribution of intimal and medial calcification to the
composite CAC score on EBCT remains unclear. Nev-
ertheless, recent data suggest that medial calcification
[(either in diabetes mellitus or end-stage renal disease
(ESRD)] is also an active cell-mediated process, involving
processes similar to those that lead to intimal calcification
[12, 13].
While little is known about the mechanisms that con-
tribute to the high calcification burden seen in the
relatively early stages of DN, there is a greater under-
standing of some of the factors involved in the setting of
ESRD. Thus, several observational studies suggest that
disordered mineral metabolism (e.g., elevated serum cal-
cium, phosphorus, or parathyroid hormone levels) or
its treatment (e.g., calcium-based phosphate binders)
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may play an important role in the high severity and
rapid progression of vascular and valvular calcification
[9, 13–18]. However, it appears that disordered mineral
metabolism is either not sufficient or not the only mech-
anism that contributes to the arterial calcification seen
in ESRD. Several novel factors such as osteoprotegrin,
a2-Heremans-Schmid protein (fetuin-A), or matrix Gla
protein, are being studied in this context [17, 19, 20].
Fetuin-A (a2-Heremans Schmid glycoprotein) is
synthesized in the liver and plays an important role in
osteogenesis. Recent experimental evidence shows that
fetuin-A may be an important mediator of insulin re-
sistance, is a negative acute-phase reactant, participates
in the recovery from acute inflammation, and is a po-
tent circulating inhibitor of the precipitation of calcium
and phosphorus [21–23]. Fetuin-A levels are significantly
lower among individuals with ESRD, and consistent with
its status as a negative acute-phase reactant, there is a sig-
nificant, inverse association between serum fetuin-A lev-
els and mortality [23]. Several lines of evidence suggest
that a deficiency of fetuin-A may contribute to the vascu-
lar calcification seen in patients with ESRD. First, exten-
sive vascular calcification is noted in fetuin-A knockout
mice in the presence of a diet rich in mineral and vita-
min D [20]. Second, the serum levels of fetuin-A are sig-
nificantly lower among patients with calciphylaxis than
among other patients with ESRD [20]. Third, the failure
of uremic human plasma to inhibit the precipitation of
calcium and phosphorus is corrected by the addition of
fetuin-A [23]. There is virtually no data regarding the re-
lationship of serum fetuin-A to the vascular calcification
burden that is apparent even in early stages of DN.
We undertook this post-hoc analysis of the data from
a cross-sectional study of CAC in nondialyzed patients
with type 2 diabetes mellitus to determine the relation-
ship of serum fetuin-A levels with vascular calcification,
as ascertained by the CAC score on EBCT.
METHODS
Patient selection and data collection
This is a cross-sectional study of CAC in a cohort of
middle-aged, nondialyzed individuals with type 2 dia-
betes mellitus. Three groups of 30 individuals between
the ages of 40 and 65 years were studied (N = 90): Latinos
with diabetes mellitus and normoalbuminuria (“diabetic
controls”), Latinos with DN, and African Americans
with DN. The details regarding this study cohort have
been previously described [11]. Stored sera (−80◦C) were
available for the measurement of serum fetuin-A in all
but two African Americans with DN (N = 88). In this
study, DN was deemed to be present using the criteria
established by the NIDDK-sponsored Family Investiga-
tion of Nephropathy in Diabetes (FIND) study, and was
defined as the presence of one of the following: (1) renal
biopsy evidence of DN with overt proteinuria (urine pro-
tein >0.5 g/day or urine protein/creatinine ratio >0.5); (2)
diabetes duration ≥10 years and urine protein excretion
>2.5 g/day or protein creatinine ratio >2.5; or (3) diabetes
duration ≥5 years, presence of diabetic retinopathy, and
urine protein excretion >1.0 g/day or protein creatinine
ratio >1.0. The highest documented urine protein excre-
tion in the patient’s medical chart was used to determine
patient eligibility.
All eligible patients who consented to participate in
the study were scheduled for an outpatient clinic visit at
the General Clinical Research Center located at the Los
Angeles Biomedical Institute at Harbor-UCLA Medi-
cal Center. All the data thus collected were used to
determine the prevalence and/or severity of traditional
(nonmodifiable: age, gender, family history of premature
cardiovascular disease; modifiable: hypertension, dys-
lipidemia, current smoking, and obesity), renal-related
[serum creatinine, estimated glomerular filtration rate
(GFR), serum calcium, phosphorus, intact parathyroid
hormone (iPTH), and 1,25 di-hydroxy vitamin D levels]
and diabetes-related [glycosylated hemoglobin (HbA1c)
and duration of type 2 diabetes mellitus] risk factors. Clin-
ical evidence of coronary artery disease (CAD) was de-
fined as the presence of one of the following: angina on
the Rose questionnaire, history of myocardial infarction,
or previous revascularization. GFR was estimated using
the abbreviated Modification of Diet in Renal Disease
(MDRD) equation [GFR (mL/min/1.73m2) = 186 × (age,
years)−0.203 × (serum creatinine, mg/dL)−1.154 × 0.742, if
female, × 1.21, if African American] [24, 25]. Serum phos-
phorus, iPTH, and 1,25 dihydroxy vitamin D levels were
measured on the day of the study visit only after the first
nine patients had been enrolled; thus, these data were
available for 24 Latinos with DN, 25 African Americans
with DN, and 30 diabetic control patients. Of note, none
of the patients enrolled in the study were being treated
with phosphate binders, vitamin D, or its analogs at the
time of the study visit.
Serum fetuin-A levels were measured on serum sam-
ples that had been stored at −80◦C. The measurements
were made using an indirect enzyme-linked im-
munosorbent assay (ELISA) technique using polyclonal
antihuman fetuin-A antiserum, secondary peroxidase-
labeled antibody, and the chromogenic substrate
ABTS (2,2-azinobis-3[ethylbenz-thiazoline-6-sulphonic
acid]; Roche, Mannheim, Germany) as described pre-
viously [23]. Briefly, serum was prediluted 10,000-fold
and coated (100lL) onto microtiter plates (MaxiSorp,
Nunc, Wiesbaden, Germany) in a 2-fold dilution series.
After incubation with the above antibodies, extinction
was measured with an automated plate reader at 405 nm
(MR5000; Dynatech, Chantilly, VA, USA). Results were
compared with an appropriate standard curve of human
fetuin-A. All samples were measured in parallel and in
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duplicates. Intra-assay and interassay coefficients of vari-
ations were below 10%.
Electron beam computed tomography
EBCT studies were performed with a C-150 XL Ul-
trafast computed tomographic scanner (Imatron, South
San Francisco, CA, USA). The protocol used for data ac-
quisition has been described previously [26]. In order to
minimize interscan variability, particularly at low scores,
scans were acquired at end-systole using electrocardio-
graphic triggering [27]. The scans of all individuals were
retrieved, and the CAC was scored by a single, highly
experienced technician, using both the Agatston as well
as volumetric method [28, 29]. The Agatston and volu-
metric scores were highly correlated in each of the three
groups studied (r = 0.99). Since most of the published
data are based upon Agatston scores, only those data are
reported.
Statistical analyses
Data are expressed as mean along with 95% confi-
dence interval (CI) for the mean; geometric means are
reported for data that are not normally distributed. The
mean fetuin-A levels were compared among the three
subgroups in the cohort (diabetic controls, Latino DN,
and African American DN) using analysis of variance
(ANOVA). The CAC score was log transformed as log
(CAC score+1) to test these associations. Partial corre-
lation coefficient was computed to test the association of
serum fetuin-A levels with CAC score, after controlling
the data for race/ethnicity and nephropathy status. Since
a significant interaction for the fetuin-A-CAC association
with nephropathy status was identified, the correlation of
serum fetuin-A with CAC score was tested in each of the
three subgroups. Finally, among individuals with DN, par-
tial correlation coefficient between serum fetuin-A lev-
els and CAC score were computed after controlling the
data for five predictors that were identified in our previ-
ous study to be related to the CAC score in this cohort
(age, gender, history of CAD, number of antihyperten-
sive medications, and duration of diabetes mellitus) [11].
Exploratory analyses were performed to test the as-
sociation of the following variables with serum fetuin-
A levels: traditional cardiovascular risk factors [age,
gender, measures of hypertension (presence/absence of
hypertension, number of antihypertensive medications,
systolic and diastolic blood pressure), dyslipidemia (pres-
ence/absence of dyslipidemia, serum total, high-density
lipoprotein, and low-density lipoprotein cholesterol and
serum triglycerides), obesity (BMI), family history of
premature cardiovascular disease, and current smoking],
history of manifest CAD, diabetes-related risk factors
(HbA1c, duration of diabetes), and renal-related risk
factors (serum creatinine, Ca, P, iPTH, and 1,25 dihy-
droxy vitamin D, creatinine, and GFR). The data on
serum low-density lipoprotein and high-density lipopro-
tein cholesterol, serum triglycerides, creatinine, phospho-
rus, and iPTH and GFR were log-transformed to achieve
approximate normal distributions. Since mean fetuin-A
levels differed among the three subgroups, these asso-
ciations were examined in each of the subgroups sepa-
rately. Pearson correlations and t tests, respectively, were
used to examine associations between fetuin-A and a
continuous or categorical subject characteristic. Partial
correlations were then used to identify characteristics in-
dependently associated with fetuin-A in each subgroup,
after adjusting for other characteristics. Additionally,
characteristics with (possibly nonsignificant) associations
with fetuin-A in the same direction for all three sub-
groups were examined in the entire cohort with partial
correlations controlling for subgroup. Such characteris-
tics that were significantly independently associated with
fetuin-A, after adjusting for other characteristics, were
identified. These two sets of identified independently as-
sociated characteristics—those significant in a particular
subgroup or those in the entire cohort and consistent
in all subgroups—were considered as potential associ-
ated characteristics. To determine if the relationships thus
determined were independent of other correlations the
analyses were repeated after adjusting the data for such
factors.
All statistical analyses were performed using SAS, ver-
sion 8.2 (SAS Institute, Cary, NC, USA) and SPSS, ver-
sion 11.5 (SPSS, Inc., Chicago, IL, USA) software. A
significance level of 0.05 was used for all analyses. No
formal correction was made for multiple statistical tests.
RESULTS
Patient characteristics
The key clinical characteristics of the 88 patients
(42 men) are summarized in Table 1. Among individ-
uals with DN, 15 (25%) had clinical evidence of CAD
(6 Latinos, 9 African Americans)—angina, 6; history of
myocardial infarction, 9; and previous revascularization,
5. Among diabetic control patients, 7 (23%) individuals
had clinical CAD—angina, 4; history of myocardial in-
farction, 5; and previous revascularization, 3.
The serum fetuin-A levels among Latino individuals
with DN (0.80 mg/mL; 95% CI: 0.72-0.88) were signifi-
cantly higher than among either African Americans with
DN (0.64 mg/mL; 95% CI: 0.58-0.71, P = 0.003) or Latino
diabetic control patients (0.63 mg/mL; 95% CI: 0.56-0.71,
P = 0.002) (Table 1). Furthermore, despite a similar sever-
ity of renal failure, Latinos with DN had significantly
higher serum phosphorus and serum triglycerides than
the African Americans (Table 1). The significance of dif-
ference in serum fetuin-A levels between Latinos and
Mehrotra and Westenfeld et al: Serum fetuin-A in nondialyzed patients: Relationship with CAC 1073
Table 1. Clinical and laboratory characteristics of the study cohort
Diabetic control patients Diabetic nephropathy
Latinos Latinos African Americans
(N = 30) (N = 30) (N = 28)
Age years 54 (51, 56) 55 (52, 57) 56 (53, 59)
Gender M/F 13/17 14/16 15/13
Urinary protein/albumin excretion
24-hour protein g/day 7.0 (5.3, 8.7) 7.4 (5.4, 9.4)
Albumin-creatinine ratio mg/mg 0.012 (0.005, 0.20)
Serum fetuin-A mg/mL b,e 0.63 (0.56, 0.71) 0.80 (0.72, 0.88) 0.64 (05.8, 0.71)
Hypertension
Prevalence% c 73% 97% 96%
Systolic arterial pressure mm Hg a 140 (132, 148) 159 (148, 170) 158 (148, 168)
Antihypertensive medications, number c 1.2 (0.7, 1.6) 2.9 (2.4, 3.4) 3.1 (2.6, 3.5)
Dyslipidemia
Prevalence% 80% 87% 86%
LDL cholesterol mg/dLd 110 (94, 128) 116 (99, 135) 108 (91, 126)
HDL cholesterol mg/dLd 41 (36, 46) 42 (37, 46) 40 (36, 46)
Triglycerides mg/dLd 150 (116, 193) 195 (142, 268) 124 (100, 154)
Body mass index kg/m2 31.6 (29.1, 34.2) 31.3 (28.4, 34.2) 31.0 (28.0, 34.0)
Renal function
Serum creatinine mg/dLc,d 0.7 (0.6, 0.8) 2.1 (1.6, 2.8) 2.5 (2.0, 3.2)
Estimated GFR mL/min/1.73m2c,d 104 (94, 114) 30 (23, 39) 30 (23, 40)
Divalent ion metabolism
Serum calcium mg/dL 9.6 (9.5, 9.7) 9.6 (9.5, 9.8) 9.7 (9.4, 9.9)
Serum phosphorus mg/dLc,e 3.6 (3.5, 3.8) 4.7 (4.2, 5.1) 3.9 (3.5, 4.3)
Serum parathyroid hormone pg/mLa,c 44 (39, 50) 106 (72, 155) 164 (106, 255)
Serum 1,25 vitamin D pg/mLc 49 (42, 55) 34 (29, 39) 33 (28, 37)
Serum albumin g/dLc 3.7 (3.6, 3.8) 3.2 (3.0, 3.3) 3.1 (2.9, 3.4)
Diabetes-related factors
Glycosylated hemoglobin % 8.6 (8.0, 9.3) 7.8 (6.8, 8.8) 7.9 (7.0, 8.8)
Duration of diabetes mellitus years 15.9 (12, 17) 16 (14, 18) 19 (15, 22)
Coronary artery calcification
Prevalence%c 63% 93% 96%
Agatston Scorec,d 11 (4, 28) 56 (22, 140) 38 (15, 95)
Data are expressed as mean with 95% confidence intervals; ageometric means are reported for variables that are not normally distributed.
Latino diabetic control patients vs. Latinos with diabetic nephropathy: aP ≤ 0.05; bP ≤ 0.01; cP ≤ 0.001.
Latino vs. African Americans with diabetic nephropathy: dP ≤ 0.05; eP ≤ 0.01.
African Americans with DN persisted, even after individ-
ually adjusting the data for either of these two variables.
Latinos with DN had significantly higher serum cre-
atinine, phosphorus, and iPTH levels, and lower GFR,
serum albumin, and 1,25 dihydroxy vitamin D levels when
compared to diabetic control patients (Table 1). The sig-
nificance of difference in serum fetuin-A levels between
Latinos with and without nephropathy persisted even af-
ter controlling for each of the individual characteristics.
Serum fetuin-A and CAC
CAC was significantly more prevalent and severe
among individuals with DN than among diabetic con-
trol patients (Table 1). Upon controlling the data for
nephropathy and ethnicity, there was a significant rela-
tionship between CAC score and serum fetuin-A levels
(r = 0.22, P = 0.038); however, there was a significant
interaction of the CAC score-serum fetuin-A relation-
ship with the nephropathy status. Thus, while there was a
positive relationship between the CAC score and serum
fetuin-A levels among each of the two subgroups with
DN (Latinos with DN, r = 0.26, P = 0.17, and African
Americans with DN, r = 0.51, P = 0.006), no such corre-
lation was demonstrable among Latino diabetic control
patients (r = 0.0, P = 0.98) (Fig. 1). Upon adjusting the
data for race/ethnicity, there was a significant correlation
between serum-fetuin-A levels and CAC (partial correla-
tion = 0.36, P = 0.006) among individuals with DN. The
five factors previously identified as significantly associ-
ated with CAC in this population (age, gender, history of
CAD, number of antihypertensive medications, and dura-
tion of diabetes) [11] remained so even after adjusting the
data for serum fetuin-A levels. Furthermore, among indi-
viduals with DN, the relationship between serum fetuin-
A levels and CAC score remained significant (partial r =
0.33, P = 0.018) even after controlling the data for these
five variables (age, gender, history of CAD, number of
antihypertensive medications, and duration of diabetes
mellitus).
Associations between serum fetuin-A and other
subject characteristics
Because the mean serum fetuin-A levels were signif-
icantly greater for the Latino DN subgroup than for
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Fig. 1. Scatter plot showing the relationship between serum fetuin-A
levels and coronary artery calcification score. Among Latino diabetic
control patients, there was no significant relationship between serum
fetuin-A and coronary artery calcification score (r = 0.0, P = 0.98).
There was a direct relationship between serum fetuin-A levels and CAC
between the Latino (r =0.27, P =0.17) and African Americans (r =0.51,
P = 0.006) with DN. Upon adjusting the data for race/ethnicity, there
was a significant, direct relationship between serum fetuin-A levels and
coronary artery calcification score (partial r = 0.36, P = 0.006).
Latino diabetic control patients and African Ameri-
cans with DN, associations between serum fetuin-A and
other subject characteristics were examined separately
in the three subgroups (Table 2). Serum triglycerides and
glomerular filtration rate were nonsignificantly positively
correlated with serum fetuin-A in all three subgroups, and
this consistency over subgroups provided independent
significant correlation (partial r: triglycerides, 0.27, P =
0.01, and GFR, 0.22, P = 0.04; Table 2) in the entire co-
hort after controlling for the subgroups. There was a sig-
nificant association between serum albumin and fetuin-A
levels in Latinos with and without nephropathy (Latinos
with DN, r = 0.53; P = 0.003) and Latino diabetic control
patients (r = 0.36, P = 0.05); no significant association
was detectable in African Americans (r = 0.13, P = 0.52)
(Table 2). The significant association between serum al-
bumin and fetuin-A persisted even when the data were
controlled for GFR. On the other hand, the correlation
between fetuin-A and GFR was reduced to a nonsignifi-
cant level, after adjusting the data for serum albumin.
There was an inverse association between systolic
blood pressure and serum fetuin-A levels in each of the
three subgroups—the relationship was significant only
among the African Americans (r = −0.52, P = 0.005),
but yielded a significant relationship for the entire study
cohort (partial r = −0.22, P = 0.039) (Table 2). Since
systolic blood pressure and GFR were significantly re-
lated, the relationship between systolic blood pressure
and serum fetuin-A was reanalyzed after controlling for
GFR. This reduced the association to a nonsignificant
level. Among Latinos with DN, both HbA1C (r = 0.43)
and 1,25 dihydroxy vitamin D (r = 0.41) were individually
significantly correlated with serum fetuin-A. However,
this association was reduced to a nonsignificant level af-
ter adjusting the data for serum albumin and duration of
diabetes. Moreover, the associations of HbA1c and serum
1,25 dihydroxy vitamin D were not discernible in other
subgroups.
DISCUSSION
This study is the first evaluation of the relationship of
serum fetuin-A in a cohort of diabetics with and with-
out nephropathy. Data derived from animal models and
patients undergoing maintenance dialysis have suggested
that CKD is associated with significantly lower serum fe-
tuin levels and this, in turn, may contribute to the progres-
sion of vascular and soft tissue calcification. This study
demonstrates that the relationship between serum fetuin-
A levels and CKD and its contribution to vascular calcifi-
cation in the setting of chronic kidney disease is far more
complex than previously thought.
Our study shows that Latinos with diabetic nephropa-
thy not undergoing maintenance dialysis have signifi-
cantly higher serum fetuin-A levels when compared to
diabetic control patients (in contrast to significantly lower
levels among patients with ESRD). Not withstanding the
relatively higher levels among individuals with DN, the
serum fetuin-A levels seem to decline with decrease in
GFR. Since our study did not include African American
diabetic control patients, it is unclear if these differences
are seen in individuals belonging to racial/ethnic groups
other than the Latinos. However, hepatic synthesis of
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Table 2. Summary of significant correlations for serum fetuin-A levels in patient subgroups and pooled data, as appropriate
Diabetic control patients Diabetic nephropathy Pooled data
Latinos (N = 30) Latinos (N = 30) African Americans (N = 28) N = 88
Serum fetuin-A mg/mLa 0.63 ± 0.19 0.80 ± 0.21 0.64 ± 0.17
Serum triglycerides mg/dL
Correlation, r 0.28 0.36 0.12 0.27
P value 0.14 0.06 0.54 0.01
GFR mL/min/1.73m2
Correlation, r 0.24 0.35 0.07 0.22
P value 0.20 0.06 0.73 0.04
Serum albumin g/dL
Correlation, r 0.36 0.53 0.13 0.30
P value 0.05 0.003 0.53 0.005
Systolic blood pressure mm Hg
Correlation, r −0.02 −0.18 −0.52 −0.22
P value 0.94 0.34 0.005 0.04
Diabetes duration years
Correlation, r −0.06 0.45 −0.04
P value 0.77 0.01 0.83
aMean ± standard deviation.
several proteins (like lipoprotein(a)) is increased in pa-
tients with proteinuric renal diseases; it is possible that
the same mechanisms may lead to relatively higher serum
fetuin-A levels among individuals with DN. Furthermore,
our data showing the direct relationship between serum
fetuin-A levels and GFR are consistent with the previ-
ous reports of low serum fetuin-A levels among individ-
uals with ESRD. Putting our data in context to previ-
ous reports suggests that serum fetuin-A levels probably
decline to subnormal levels only late during the course
of progression of diabetic CKD (i.e., after approaching
ESRD).
Another unexpected finding in this biracial cohort of
diabetics with DN was a direct relationship between
serum fetuin-A levels and the CAC score. This relation-
ship is the opposite of what would be expected from
the animal studies or the studies in humans with ESRD
[23]. However, these differences may indicate a differ-
ent pathogenetic role of fetuin-A in different stages of
CKD. With respect to vascular calcification, there appear
to be two relevant effects of fetuin-A: (1) it prevents the
precipitation of calcium and phosphorus; and (2) it is an
important mediator of insulin resistance. Experimental
evidence suggests that fetuin-A inhibits the insulin recep-
tor tyrosine kinase and, thus, prevents insulin-mediated
autophosphorylation of the insulin receptor [30]. This, in
turn, would result in insulin resistance [31]. The human
fetuin-A gene is localized to chromosome 3q27, a region
that has been linked to susceptibility for type 2 diabetes
as well as the metabolic syndrome [32, 33]. Furthermore,
fetuin-A knockout mice demonstrate improved insulin
sensitivity and resistance to weight gain and fat accumula-
tion when fed a high-fat diet [22]. Finally, serum fetuin-A
levels are significantly higher among women with ges-
tational diabetes mellitus when compared to otherwise
healthy pregnant women or nonpregnant control patients
[34]. Our observation of a direct association between
serum fetuin-A and triglyceride levels is consistent with
a possible pathogenetic role for fetuin-A in exacerbat-
ing the insulin resistance associated with diabetic chronic
kidney disease.
Thus, it is possible that in the presence of nephropathy,
fetuin-A exacerbates insulin resistance and, thus, worsens
the proatherogenic milieu among individuals with type 2
diabetes mellitus. This may, in turn, promote atheroscle-
rosis and lead to intimal calcification of the coronary
arteries. With progressive loss of GFR, serum levels of
fetuin-A seem to decline. In patients with stage 4 or 5
CKD and hyperphosphatemia, this fetuin-A deficiency
may lead to the precipitation of calcium and phosphorus
and worsening of coronary calcification.
It is possible, however, that rather than fetuin-A lead-
ing to greater CAC, the converse may be true. In this
context, an alternative explanation of the positive rela-
tionship between serum fetuin-A and CAC scores could
be that hepatic fetuin-A up-regulation may be a feedback
defense mechanism protecting against excessive vascu-
lar calcifications in early stages of diabetic nephropathy.
This view is supported by immunohistochemical findings
showing strongly increased fetuin-A deposition, but not
expression, in areas of vascular calcification [abstract;
Moe et al, J Am Soc Nephrol 14:692A, 2003]. While in
ESRD patients CAC scores of >400 are frequently found,
the mean scores in our cohort were 11 (diabetic control
patients), 56 (Latinos with DN), and 38 (AA with DN),
respectively. The more extreme calcification burden in
ESRD patients may thus exhaust the fetuin-A system,
causing deficiency of the circulating fetuin-A, and conse-
quently, starting a vicious cycle of even more progressive
extraosseous calcification. In contrast, fetuin-A levels
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may be a marker of a physiologic attempt to counteract
early vascular calcification. If this interpretation was cor-
rect, future research identifying circulating fetuin-A reg-
ulatory factors and an understanding of the hepatocellu-
lar capacity of hepatic fetuin-A synthesis might implicate
new anti-atherogenic therapies.
Our data do not permit us to provide explanations for
some of the other findings reported in this study. First, be-
cause the direct relationship between fetuin-A and CAC
was restricted to individuals with DN, it appears that
factors that covary with the appearance of proteinuria
may facilitate the actions or feedback mechanisms associ-
ated with fetuin-A. Second, African Americans with DN
had significantly lower fetuin-A levels than Latinos. Fur-
thermore, African Americans with DN had significantly
lower serum triglyceride levels than Latinos—a finding
that has been well documented by other investigators [35,
36]. The observation of lower fetuin-A levels in African
Americans warrants further investigation in larger co-
horts because lower CAC scores were previously and
consistently reported in this racial/ethnic group [37, 38].
In this study, the trend toward lower CAC scores among
African Americans with DN did not reach statistical sig-
nificance, probably because of relatively small numbers
of patients in each group. Finally, our study shows a direct
relationship between serum fetuin-A and albumin levels.
Both fetuin-A and albumin are negative acute-phase re-
actants [23]. It is likely, then, that the direct association
between the levels of these two proteins is confounded
by microinflammation. However, this possibility was not
tested directly in our study. Larger studies enrolling mul-
tiethnic populations are needed to further corroborate
and clarify all the findings listed above.
There are several limitations to this study. First, no for-
mal assessments of the degree of insulin resistance were
made. However, the presence of CKD is known to be as-
sociated with an increase in insulin resistance at the post-
receptor level, similar to what has been described as an
effect of fetuin-A. Second, there was no control group of
nondiabetic individuals with/without renal disease. Third,
an indirect estimation of GFR was used to determine re-
nal function. Some recent studies have raised the concern
that the relationship of cardiovascular risk factors (e.g.,
age, body weight, and body mass index) and renal func-
tion may be affected by the method selected to estimate
renal function [39]. However, the equation used in this
study has been validated in a biracial population, and the
direction of change reported in this study is consistent
with significantly lower serum fetuin-A levels in patients
with ESRD [23, 24, 40]. Fourth, we did not make any
assessments of the functional activity of fetuin-A in this
cohort. The in vitro studies suggest that only the phos-
phorylated form of fetuin-A is functionally active, and in
normal humans, it is estimated that 20% of the circulating
fetuin-A is phosphorylated [30, 41–43]. It is unclear if the
presence of diabetes mellitus or CKD modifies the pro-
portion of circulating fetuin-A that is phosphorylated.
Furthermore, in the setting of type 2 diabetes, the pro-
tein may be hyperglycosylated; this, in turn, may modify
the functional activity of fetuin-A. Finally, because these
analyses were exploratory in nature, multiple compar-
isons were made, predisposing to the possibility of false-
positive observations. The latter is less likely, given that
our findings are consistent with the biologic understand-
ing of fetuin-A. Nevertheless, these observations require
confirmation in larger study populations.
CONCLUSION
This study shows that the relationship of serum fetuin-
A levels to the presence of CKD and its role in vascular
calcification is far more complex than suggested by previ-
ous studies. In conjunction with the previously published
data, the direct association between serum fetuin-A levels
and CAC in nondialyzed patients with DN would suggest
that the high fetuin-A levels may be proatherogenic, pre-
sumably by inducing and/or enhancing insulin resistance.
Thus, the role of fetuin-A in inducing CAC may differ at
different stages of chronic kidney disease.
ACKNOWLEDGMENTS
This paper was supported by: Clinical Research Feasibility Funds
from the GCRC at Harbor-UCLA Medical Center; Seed Grant from
the Research Committee of the Los Angeles Biomedical Institue at
Harbor-UCLA Medical Center; Harbor-UCLA General Clinical Re-
search Center grant M01-RR00425 from the National Centers for
Research Resources at the NIH; and Rajnish Mehrotra, M.D., was sup-
ported by a K23 grant (RR18298-01A1) from the National Center for
Research Resources at the NIH. Part of this work was presented at the
36th Annual Conference of the American Society of Nephrology at San
Diego, California, in November 2003.
Reprint requests to Rajnish Mehrotra, M.D., Division of Nephrol-
ogy and Hypertension, Harbor-UCLA Medical Center, 1124 W. Carson
Street, Torrance, CA 90502.
E-mail: rmehrotra@labiomed.org
REFERENCES
1. RUMBERGER JA, SIMONS DB, FITZPATRICK LA, et al: Coronary artery
calcium area by electron-beam computed tomography and coronary
atherosclerotic plaque area. A histopathologic correlative study.
Circulation 92:2157–2162, 1995
2. BAUMGART D, SCHMERMUND A, GOERGE G, et al: Comparison of elec-
tron beam computed tomography with intracoronary ultrasound
and coronary angiography for detection of coronary atherosclero-
sis. J Am Coll Cardiol 30:57–64, 1997
3. BUDOFF MJ: Prognostic value of coronary artery calcification.
JCOM 8:42–48, 2001
4. GREENLAND P, LABREE L, AZEN SP, et al: Coronary artery cal-
cium score combined with Framingham score for risk prediction
in asymptomatic individuals. JAMA 291:210–215, 2003
5. BOSTROM K: Insights into the mechanism of vascular calcification.
Am J Cardiol 88:20E–22E, 2001
6. WALLIN R, WAJIH N, GREENWOOD GT, SANE DC: Arterial calcifica-
tion: A review of mechanisms, animal models, and the prospects for
therapy. Med Res Rev 21:274–301, 2001
Mehrotra and Westenfeld et al: Serum fetuin-A in nondialyzed patients: Relationship with CAC 1077
7. BRAUN J, OLDENDORF M, MOSHAGE W, et al: Electron beam com-
puted tomography in the evaluation of cardiac calcification in
chronic dialysis patients. Am J Kidney Dis 27:394–401, 1996
8. GOODMAN WG, SALUSKY IB: Non-invasive assessments of cardio-
vascular disease in patients with renal failure. Curr Opin Nephrol
Hypertens 10:365–369, 2001
9. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in
adult hemodialysis patients. A link between end-stage renal disease
and cardiovascular disease? J Am Coll Cardiol 39:695–701, 2002
10. MERJANIAN R, BUDOFF M, ADLER S, et al: Coronary artery, aortic
wall and valvular calcification in non-dialyzed patients with type 2
diabetes and renal disease. Kidney Int 64:263–271, 2003
11. MEHROTRA R, BUDOFF MJ, CHRISTENSON P, et al: Determinants
of coronary artery calcification in diabetics with and without
nephropathy. Kidney Int 66, in press
12. SHANAHAN CM, CARY NR, SALISBURY JR, et al: Medial localization
of mineralization-regulating proteins in association with Moncke-
berg’s sclerosis: Evidence for smooth muscle cell-mediated vascular
calcification. Circulation 100:2168–2176, 1999
13. MOE SM, O’NEILL KD, DUAN D, et al: Medial artery calcification
in ESRD patients is associated with deposition of bone matrix pro-
teins. Kidney Int 61:638–647, 2002
14. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery cal-
cification in young adults with end-stage renal disease who are un-
dergoing dialysis. N Engl J Med 342:1478–1483, 2000
15. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the pro-
gression of coronary and aortic calcification in hemodialysis pa-
tients. Kidney Int 62:245–252, 2002
16. OH J, WUNSCH R, TURZER M, et al: Advanced coronary and carotid
arteriopathy in young adults with childhood-onset chronic renal
failure. Circulation 106:100–105, 2002
17. NITTA K, AKIBA T, UCHIDA K, et al: The progression of vascular
calcification and serum osteoprotegerin levels in patients on long-
term hemodialysis. Am J Kidney Dis 42:303–309, 2003
18. SHIGEMATSU T, KONO T, SATOH K, et al: Phosphate overload acceler-
ates vascular calcium deposition in end-stage renal disease patients.
Nephrol Dial Transplant 18(Suppl 3):86–89, 2003
19. KETTELER M, WANNER C, METZGER T, et al: Deficiencies of calcium-
regulatory-proteins in dialysis patients: A novel concept of cardio-
vascular calcification in uremia. Kidney Int 63:S84–S87, 2003
20. SCHAFER C, HEISS A, SCHWARZ A, et al: The serum protein alpha-
2 Heremans-Schmid glycoprotein/fetuin-A is a systemically acting
inhibitor of ectopic calcification. J Clin Invest 112:357–366, 2003
21. WANG H, ZHANG M, BIANCHI M, et al: Fetuin (alpha2-
HS-glycoprotein) opsonizes cationic macrophage deactivating
molecules. Proc Natl Acad Sci USA 95:14429–14434, 1998
22. MATTHEWS ST, SINGH GP, RANALLETTA M, et al: Improved insulin
sensitivity and resistance to weight gain in mice null for the Ahsg
gene. Diabetes 51:2450–2458, 2002
23. KETTELER M, BONGARTZ P, WESTENFELD R, et al: Association of
low fetuin-A (AHSG) concentrations in serum with cardiovascu-
lar mortality in patients on dialysis: A cross-sectional study. Lancet
361:827–833, 2003
24. LEVEY AS, BOSCH JP, LEWIS JB, et al: A more accurate method to
estimate glomerular filtration rate from serum creatinine: A new
prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 130:461–470, 1999
25. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines
for chronic kidney disease: Evaluation, classification and stratifica-
tion. Am J Kidney Dis 39:S1–S266, 2002
26. MAO S, BUDOFF MJ, BAKHSHESHI H, LIU SC: Improved reproducibil-
ity of coronary artery calcium scoring by electron beam tomogra-
phy with a new electrocardiographic trigger method. Invest Radiol
36:363–367, 2001
27. LU B, ZHUANG N, MAO S, et al: EKG-triggered CT data acquistion
to reduce variability in coronary arterial calcium score. Radiology
224:838–844, 2002
28. AGATSTON AS, JANOWITZ WR, HILDNER FJ, et al: Quantification of
coronary artery calcium using ultrafast computed tomography. J
Am Coll Cardiol 15:827–832, 1990
29. CALLISTER TQ, COOIL B, RAYA SP, et al: Coronary artery disease:
Improved reproducibility of calcium scoring with an electron-beam
CT volumetric method. Radiology 208:807–814, 1998
30. AUBERGER P, FALQUERHO L, CONTERES JO, et al: Characterization
of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA
cloning, purification, and anti-mitogenic activity. Cell 58:631–640,
1989
31. CHEN H, SRINIVAS PR, CONG LN, et al: Alpha2-Heremans Schmid
glycoprotein inhibits insulin-stimulated Elk-1 phosphorylation, but
not glucose transport, in rat adipose cells. Endocrinology 139:4147–
4154, 1998
32. VIONNET N, HANI E-H, DUPONT S, et al: Genomewide search for
type 2 diabetes-susceptibility genes in French whites: Evidence for
a novel susceptibility locus for early-onset diabetes on chromosome
3q27-qter and independent replication of a type 2-diabetes locus on
chromosome 1q21-q24. Am J Hum Genet 67:1470–1480, 2000
33. KISSEBAH AH, SONNENBERG GE, MYKLEBUST J, et al: Quantitative
trait loci on chromosomes 3 and 17 influence phenotypes of the
metabolic syndrome. Proc Natl Acad Sci U S A 97:14478–14483,
2000
34. KALABAY L, CSEH K, PAJOR A, et al: Correlation of maternal serum
fetuin/alpha2-HS-glycoprotein concentration with maternal insulin
resistance and anthropometric parameters of neonates in normal
pregnancy and gestational diabetes. Eur J Endocrinol 147:243–248,
2002
35. SHARMA MD, PAVLIK VN: Dyslipidaemia in African Americans, His-
panics and whites with type 2 diabetes mellitus and hypertension.
Diabetes Obes Metab 3:41–45, 2001
36. FRONTINI MG SS, ELKASABANY A, BERENSON GS: Distribution and
cardiovascular risk correlates of serum triglycerides in young adults
from a biracial community: The Bogalusa Heart Study. Atheroscle-
rosis 155:201–209, 2001
37. DETRANO RC, WONG ND, DOHERTY TM, SHAVELLE R: Prognostic
significance of coronary calcific deposits in asymptomatic high-risk
subjects. Am J Med 102:344–349, 1997
38. BUDOFF MJ, YANG TP, SHAVELLE RM, et al: Ethnic differences in
coronary atherosclerosis. J Am Coll Cardiol 39:408–412, 2002
39. VERHAVE JC, GANSEVOORT RT, HILLEGE HL, et al: Drawbacks of
the use of indirect estimates of renal function to evaluate the effect
of risk factors on renal function. J Am Soc Nephrol 15:1316–1322,
2004
40. LEWIS J, AGODOA L, CHEEK D, et al: Comparison of cross-sectional
renal function measurements in African Americans with hyperten-
sive nephrosclerosis and of primary formulas to estimate glomerular
filtration rate. Am J Kidney Dis 38:744–753, 2001
41. KALABAY L, MATHUR S, BOBIN S, ARNAUD P: Electrophoretic and
isoelectric focusing analysis of human recombinant alpha 2–HS gly-
coprotein produced in insect cells: Analysis of the post-translational
events. Electrophoresis 17:529–532, 1996
42. OHNISHI T, NAKAMURA O, ARAKAKI N, DAIKUHARA Y: Effect
of phosphorylated rat fetuin on the growth of hepatocytes in
primary culture in the presence of human hepatocyte-growth
factor. Evidence that phosphorylated fetuin is a natural modu-
lator of hepatocyte-growth factor. Eur J Biochem 243:753–761,
1997
43. HAGLUND AC, EK B, EK P: Phosphorylation of human plasma
alpha2-Heremans-Schmid glycoprotein (human fetuin) in vivo.
Biochem J 357:437–445, 2001
